Steven Cohen's CADL Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 107,211 shares of Candel Therapeutics, Inc. (CADL) worth $525,334, representing 0.00% of the portfolio. First purchased in 2022-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Steven Cohen has maintained this position in CADL for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 107,211 shares. Largest reduction occurred in Q4 2022, reducing 403,131 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Candel Therapeutics (CADL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Candel Therapeutics (CADL) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +107,211 | New Buy | 107,211 | $4.90 |
| Q4 2022 | -403,131 | Sold Out | 0 | $0.00 |
| Q3 2022 | -339,951 | Reduce 45.75% | 403,131 | $3.14 |
| Q2 2022 | +743,082 | New Buy | 743,082 | $3.24 |
Steven Cohen's Candel Therapeutics Investment FAQs
Steven Cohen first purchased Candel Therapeutics, Inc. (CADL) in Q2 2022, acquiring 743,082 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Candel Therapeutics, Inc. (CADL) for 4 quarters since Q2 2022.
Steven Cohen's largest addition to Candel Therapeutics, Inc. (CADL) was in Q2 2022, adding 743,082 shares worth $2.41 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 107,211 shares of Candel Therapeutics, Inc. (CADL), valued at approximately $525,334.
As of the Q1 2026 filing, Candel Therapeutics, Inc. (CADL) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Candel Therapeutics, Inc. (CADL) was 743,082 shares, as reported at the end of Q2 2022.